Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol …
Eying growth in oncology, Astellas has suffered an R&D setback for acute myeloid leukemia drug Xospata (gilteritinib). The med flunked a combo trial with Bristol …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.